China Universal Asset Management Co. Ltd. Boosts Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

China Universal Asset Management Co. Ltd. grew its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 10.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,480 shares of the biopharmaceutical company’s stock after purchasing an additional 2,157 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Intra-Cellular Therapies were worth $1,878,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. True Wealth Design LLC purchased a new stake in Intra-Cellular Therapies during the third quarter worth about $32,000. GAMMA Investing LLC increased its stake in shares of Intra-Cellular Therapies by 46.3% during the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 240 shares during the last quarter. Capital Performance Advisors LLP bought a new stake in shares of Intra-Cellular Therapies in the 3rd quarter worth approximately $74,000. Wilmington Savings Fund Society FSB purchased a new position in Intra-Cellular Therapies in the third quarter valued at approximately $97,000. Finally, Quarry LP grew its holdings in Intra-Cellular Therapies by 260.0% during the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 1,300 shares during the period. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Stock Up 0.1 %

NASDAQ:ITCI opened at $127.08 on Friday. The business’s 50-day moving average price is $97.45 and its two-hundred day moving average price is $84.45. Intra-Cellular Therapies, Inc. has a twelve month low of $62.78 and a twelve month high of $128.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The company had revenue of $175.40 million during the quarter, compared to analysts’ expectations of $172.30 million. During the same period in the prior year, the business earned ($0.25) earnings per share. The company’s revenue for the quarter was up 39.0% compared to the same quarter last year. On average, analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Insider Transactions at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $91,834,228.20. This represents a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Michael Halstead sold 22,869 shares of Intra-Cellular Therapies stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total transaction of $2,038,085.28. The disclosure for this sale can be found here. Insiders own 2.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ITCI shares. StockNews.com started coverage on Intra-Cellular Therapies in a research note on Friday. They issued a “hold” rating on the stock. Piper Sandler reaffirmed a “neutral” rating and set a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Baird R W downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their price target for the company from $119.00 to $132.00 in a research note on Friday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a research note on Monday, November 4th. Nine equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $103.62.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.